Regentis Biomaterials Ltd. announced the expansion of its European clinical site network into Italy, Germany, Serbia, Slovenia, and Romania to support its commercial launch of GelrinC®, which has CE Mark approval for knee cartilage repair, and ongoing clinical programs including a Phase III FDA study over 50% enrolled. This strengthens engagement with leading orthopedic surgeons and centers of excellence ahead of the 2026 European launch.
Key takeaways
Expanded European clinical sites to Italy (Humanitas Milan, Fondazione I.R.C.C.S. Pavia), Germany (University Regensburg), Serbia (Clinical Center of Vojvodina), Slovenia (University of Ljubljana), Romania (Timiş County Timişoara)
GelrinC® has CE Mark approval for knee cartilage repair; commercial launch slated for Europe in 2026
Phase III FDA study for GelrinC® has completed over 50% enrollment
Expansion supports commercial partner attraction and clinical adoption in high-potential regions